Positive News SentimentPositive NewsNASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Forecast, Price & News $9.36 +0.12 (+1.30%) (As of 05/26/2023 08:48 PM ET) Add Compare Share Share Today's Range$8.71▼$9.3750-Day Range$8.11▼$12.2052-Week Range$2.25▼$16.77Volume23,700 shsAverage Volume22,552 shsMarket Capitalization$334.06 millionP/E RatioN/ADividend YieldN/APrice Target$18.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vigil Neuroscience MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside100.9% Upside$18.80 Price TargetShort InterestBearish3.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.22) to ($2.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector721st out of 1,012 stocksBiological Products, Except Diagnostic Industry113th out of 169 stocks 3.4 Analyst's Opinion Consensus RatingVigil Neuroscience has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.80, Vigil Neuroscience has a forecasted upside of 100.9% from its current price of $9.36.Amount of Analyst CoverageVigil Neuroscience has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted3.87% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 22.8, which indicates bearish sentiment.Change versus previous monthShort interest in Vigil Neuroscience has recently increased by 4.37%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIGL. Previous Next 2.7 News and Social Media Coverage News SentimentVigil Neuroscience has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vigil Neuroscience this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders46.63% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.91% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vigil Neuroscience are expected to decrease in the coming year, from ($2.22) to ($2.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vigil Neuroscience (NASDAQ:VIGL) StockVigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.Read More Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Stock News HeadlinesMay 17, 2023 | americanbankingnews.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Earn FY2023 Earnings of ($2.14) Per ShareMay 16, 2023 | americanbankingnews.comVigil Neuroscience, Inc. Forecasted to Earn FY2023 Earnings of ($1.85) Per Share (NASDAQ:VIGL)May 29, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 13, 2023 | americanbankingnews.comVigil Neuroscience, Inc. Expected to Post Q1 2024 Earnings of ($0.51) Per Share (NASDAQ:VIGL)May 12, 2023 | msn.comVigil Neuroscience: Q1 Earnings InsightsMay 11, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Vigil Neuroscience Inc (VIGL)May 10, 2023 | finanznachrichten.deVigil Neuroscience, Inc.: Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 10, 2023 | finance.yahoo.comVigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 29, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 9, 2023 | finance.yahoo.comVigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of DirectorsMay 8, 2023 | finance.yahoo.comVigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)May 8, 2023 | finance.yahoo.comVigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth PlansApril 15, 2023 | americanbankingnews.comComparing Revolution Medicines (NASDAQ:RVMD) & Vigil Neuroscience (NASDAQ:VIGL)April 6, 2023 | americanbankingnews.comERYTECH Pharma (NASDAQ:ERYP) vs. Vigil Neuroscience (NASDAQ:VIGL) Financial ReviewApril 5, 2023 | americanbankingnews.comVigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by WedbushApril 3, 2023 | benzinga.comWhat 4 Analyst Ratings Have To Say About Vigil NeuroscienceMarch 31, 2023 | msn.comMizuho Initiates Coverage of Vigil Neuroscience (VIGL) with Buy RecommendationMarch 31, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cardinal Health (CAH), Alcon (ALC) and Vigil Neuroscience Inc (VIGL)March 31, 2023 | americanbankingnews.comVigil Neuroscience (NASDAQ:VIGL) Coverage Initiated by Analysts at MizuhoMarch 30, 2023 | markets.businessinsider.comVigil Neuroscience Inc (VIGL) Receives a New Rating from Mizuho SecuritiesMarch 30, 2023 | seekingalpha.comVigil surges after FDA lifts partial hold on neurological disorder drug VGL101March 30, 2023 | finance.yahoo.comVigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101March 29, 2023 | americanbankingnews.comVigil Neuroscience (NASDAQ:VIGL) PT Raised to $13.00 at Morgan StanleyMarch 28, 2023 | americanbankingnews.comComparing Vaxart (NASDAQ:VXRT) and Vigil Neuroscience (NASDAQ:VIGL)March 26, 2023 | americanbankingnews.comVigil Neuroscience, Inc. to Post Q1 2023 Earnings of ($0.45) Per Share, HC Wainwright Forecasts (NASDAQ:VIGL)March 23, 2023 | benzinga.comVigil Neuroscience Stock (NASDAQ:VIGL), DividendsMarch 23, 2023 | americanbankingnews.comVigil Neuroscience, Inc. Expected to Earn Q1 2023 Earnings of ($0.49) Per Share (NASDAQ:VIGL)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Company Calendar Last Earnings3/21/2023Today5/29/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VIGL CUSIPN/A CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.80 High Stock Price Forecast$24.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+100.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-40.60% Return on Assets-37.99% Debt Debt-to-Equity RatioN/A Current Ratio23.30 Quick Ratio23.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / Book1.95Miscellaneous Outstanding Shares35,690,000Free Float19,045,000Market Cap$334.06 million OptionableNot Optionable Beta3.33 Key ExecutivesDr. Ivana Magovcevic-Liebisch J.D. (Age 56)Ph.D., Pres, CEO & Director Comp: $713.25kMs. Jennifer Ziolkowski CPA (Age 49)CPA, Chief Financial Officer Comp: $518.04kDr. Spyridon Papapetropoulos M.D. (Age 50)Ph.D., Chief Medical Officer Comp: $601.74kPark Guo CPAAccounting Mang.Kelly Neelon Ph.D.VP of CMC & Technical OperationsMs. Sarah CarmodyVP of Investor Relations & Corp. CommunicationsMr. Christopher Verni J.D. (Age 48)Gen. Counsel April Effort M.B.A.M.S., Head of Corp. Devel.Mr. Evan A. Thackaberry DABT (Age 50)Ph.D., Sr. VP & Head of Early Devel. Mr. Charles MaggsHead of FP&AMore ExecutivesKey CompetitorsKodiak SciencesNASDAQ:KODCullinan OncologyNASDAQ:CGEMDBV TechnologiesNASDAQ:DBVTCoherus BioSciencesNASDAQ:CHRSCabaletta BioNASDAQ:CABAView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 8,625 shares on 5/16/2023Ownership: 0.315%Susquehanna International Group LLPBought 31,343 shares on 5/16/2023Ownership: 0.165%Jane Street Group LLCBought 27,184 shares on 5/16/2023Ownership: 0.076%Bank of America Corp DEBought 9,426 shares on 5/12/2023Ownership: 0.054%Citigroup Inc.Sold 2,529 shares on 5/11/2023Ownership: 0.256%View All Insider TransactionsView All Institutional Transactions VIGL Stock - Frequently Asked Questions Should I buy or sell Vigil Neuroscience stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VIGL shares. View VIGL analyst ratings or view top-rated stocks. What is Vigil Neuroscience's stock price forecast for 2023? 5 equities research analysts have issued 1-year target prices for Vigil Neuroscience's shares. Their VIGL share price forecasts range from $13.00 to $24.00. On average, they expect the company's share price to reach $18.80 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price. View analysts price targets for VIGL or view top-rated stocks among Wall Street analysts. How have VIGL shares performed in 2023? Vigil Neuroscience's stock was trading at $12.50 at the start of the year. Since then, VIGL stock has decreased by 25.1% and is now trading at $9.36. View the best growth stocks for 2023 here. When is Vigil Neuroscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our VIGL earnings forecast. How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) posted its earnings results on Tuesday, March, 21st. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.14. When did Vigil Neuroscience IPO? (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share. What is Vigil Neuroscience's stock symbol? Vigil Neuroscience trades on the NASDAQ under the ticker symbol "VIGL." Who are Vigil Neuroscience's major shareholders? Vigil Neuroscience's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.32%), Barclays PLC (0.29%), Citigroup Inc. (0.26%), Susquehanna International Group LLP (0.16%), Jane Street Group LLC (0.08%) and Bank of America Corp DE (0.05%). Insiders that own company stock include Christopher Verni, Clay Thorp, Evan Thackaberry, Ivana Magovcevic-Liebisch and Spyros Papapetropoulos. View institutional ownership trends. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vigil Neuroscience's stock price today? One share of VIGL stock can currently be purchased for approximately $9.36. How much money does Vigil Neuroscience make? Vigil Neuroscience (NASDAQ:VIGL) has a market capitalization of $334.06 million. The company earns $-68,310,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. How many employees does Vigil Neuroscience have? The company employs 2,021 workers across the globe. How can I contact Vigil Neuroscience? The official website for the company is vigilneuro.com. The company can be reached via phone at 857-254-4445 or via email at scarmody@vigilneuro.com. This page (NASDAQ:VIGL) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.